Basis of Presentation and Summary of Significant Accounting Policies (Policies) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Basis of Presentation and Summary of Significant Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Basis of Presentation | Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included. The results of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for the full year or any future period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reverse Stock Split | Reverse Stock Split
On or about July 23, 2026, the Company filed a certificate of amendment to its certificate of incorporation to effect a 1-for-10 reverse stock split of its issued and outstanding shares of common stock and preferred stock, which became effective on July 24, 2026. The same certificate of amendment reduced the par value per share of the common stock and the preferred stock from $0.01 to $0.001, one of the corporate actions approved by the stockholder written consent described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Because the reduction in par value was effected by the same instrument as the reverse stock split, it has been given retroactive effect for all periods presented together with the split, with the resulting reduction in stated capital of $20,311 on the shares outstanding at June 30, 2026, which were unchanged at the July 24, 2026 effective date, and $18,047 at December 31, 2025 recorded as an increase in additional paid-in capital. Total shareholders’ equity is not affected. All share, per-share and par-value amounts in these condensed consolidated financial statements, and in these notes, have been retroactively adjusted to give effect to the reverse stock split for all periods presented, with the reduction in stated par value recorded as an increase in additional paid-in capital. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Principals of Consolidation | Principals of Consolidation
The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MindWave Innovations Inc. and its subsidiaries and Nexus Global Partners Inc., and the accounts of Lokahi Therapeutics Inc. through July 14, 2026, the date of deconsolidation, measured using its June 30, 2026 balances (see Note 3). All significant intercompany accounts and transactions have been eliminated in consolidation. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Liquidity | Liquidity
The Company has incurred recurring losses from operations and negative cash flows from operating activities. For the nine months ended September 30, 2026 the Company incurred a net loss of $21,586,816 and used $7,953,510 of cash in operating activities, and as of September 30, 2026 the Company had an accumulated deficit of $31,979,877 and cash and cash equivalents of $17,912. The Company’s liquidity is substantially dependent on the value and liquidity of its digital-asset holdings, on its ability to raise additional capital, and on its ability to refinance or extend its senior secured convertible note, which matures on December 8, 2026 and was subject to a forbearance arrangement that expired on June 30, 2026 (see Note 8). These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. Management’s plans include raising additional equity or debt capital, monetizing digital assets, and managing operating expenditures; however, there can be no assurance that such plans will be successful. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Use of Estimates | Use of Estimates
The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Significant estimates include the fair value of digital assets (in particular the NILA token), the fair value of the Company’s investment in Glucotrack, the fair value of the embedded conversion feature accounted for as a derivative liability, the effective interest rates used to accrete debt discounts, the incremental borrowing rate used to measure lease liabilities, and the valuation of share-based payments. Actual results could differ from those estimates. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Digital Assets | Digital Assets
The Company accounts for its holdings of crypto assets in accordance with ASC 350-60, Intangibles — Goodwill and Other — Crypto Assets, as amended by ASU 2023-08. Crypto assets within the scope of ASC 350-60 are measured at fair value at each reporting date, with changes in fair value recognized in the condensed consolidated statements of operations as unrealized gains or losses. Gains and losses realized on sales are determined on a specific-identification basis and are presented separately. Digital assets held for market-making activity, and the corresponding costs of those activities, are presented net within trading gains, net. Digital assets received under the Company’s digital asset yield arrangements are recognized at fair value on the date of receipt, presented within revenue as digital asset yield income (see Note 4), and are thereafter measured at fair value under ASC 350-60.
The Company’s digital assets consisted of the following:
Other exchange wallet balances represent residual quantities of various tokens held in the Company’s accounts at digital-asset exchanges, none of which is individually material. The quoted price of the NILA Tokens declined from $0.08123 per token at December 31, 2025 to $0.07800 per token at September 30, 2026, and that of Bitcoin from $88,318.95 to $83,779.72 per unit; the decrease in the carrying amount of the NILA Tokens reflects both that price decline and the 40,942,936 tokens disposed of during the period.
During the three and nine months ended September 30, 2026 the Company received 5.00 and 9.84 bitcoin, respectively, under a digital asset yield arrangement (see Note 4) and recognized $418,899 and $701,630, respectively, of digital asset yield income. digital assets were received as yield in the comparative 2025 periods. The 4.84 bitcoin received on June 30, 2026 were measured at the quoted price on that date of $58,415.80 per unit, and the 5.00 bitcoin received in September 2026 were measured at $83,779.72 per unit, the quoted price on September 30, 2026. Any difference between that price and the quoted price on the date each unit was received would reclassify between digital asset yield income and the unrealized gain or loss from changes in fair value of digital assets, with no effect on income (loss) from continuing operations, net income (loss), total digital assets, total assets or shareholders’ equity for any period presented.
Activity in digital assets for the nine months ended September 30, 2026 was as follows: During that period the Company disposed of 40,942,936 NILA Tokens — 340,746 in the first quarter, 38,473,542 in the second and 2,128,648 in the third — with gross proceeds in the second quarter of $3,077,883, and transferred a net 100,121 NILA Tokens between its own wallets. In September 2026 the Company exchanged 8,051,497 Tether for 97.02 bitcoin. The Company made no other purchases of digital assets during the period, and no Bitcoin was sold.
There were digital assets pledged as collateral as of September 30, 2026 or December 31, 2025, and there were restrictions on the sale of the Company’s digital assets other than market liquidity. The carrying amount of digital assets decreased by $7,461,898 during the nine months ended September 30, 2026. Bitcoin holdings increased from 1,000.00 units to 1,106.86 units, comprising 9.84 units received as digital asset yield income and 97.02 units received in exchange for Tether, and their carrying amount increased from $88,318,950 to $92,732,430; the carrying amount of the NILA Tokens decreased from $55,075,066 to $49,683,723; and Tether holdings decreased from $6,484,632 to $0 following the exchange. The cost basis of the Company’s digital assets is the fair value assigned to them in the December 1, 2025 MindWave asset acquisition, adjusted for subsequent additions and dispositions. As of September 30, 2026 the cost basis of the Bitcoin holdings was $99,591,327, comprising $90,838,200 assigned to the 1,000.00 units acquired in that transaction, $701,630 for the 9.84 units received as digital asset yield income and $8,051,497 for the 97.02 units received in exchange for Tether; no Bitcoin was sold during the period. The NILA Tokens acquired in that transaction were assigned a cost basis of $50,804,304, of which the portion relating to tokens sold has been relieved on disposition. Cumulative realized gains recognized on sales of digital assets since the December 1, 2025 acquisition date were $5,929,223, comprising $4,197,394 for the period from December 1 through December 31, 2025 and $1,731,829 for the nine months ended September 30, 2026. No cumulative realized losses have been recognized. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value Measurement | Fair Value Measurement
ASC 820, Fair Value Measurement, establishes a three-level hierarchy that prioritizes the inputs used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities; Level 2 — observable inputs other than Level 1 prices, including quoted prices for similar assets or liabilities or quoted prices in markets that are not active; and Level 3 — unobservable inputs supported by little or no market activity. Bitcoin and Tether are measured using quoted prices from principal active exchange markets and are classified within Level 1. The NILA token trades in markets that are not active for the size of the Company’s position; its fair value is measured using observable quoted transaction prices for the token and is classified within Level 2. The derivative liability arising from the embedded conversion feature of the Company’s convertible note is measured using a Monte Carlo simulation and is classified within Level 3. Consistent with the determination made as of December 31, 2025, the limited number of trading venues on which the NILA token trades and its daily trading volume relative to the size of the Company’s position indicate that the market for the token does not meet the active market threshold required for Level 1 classification; the exchange-quoted prices used are observable inputs corroborated by transaction data. The Company’s investment in Glucotrack common stock is measured using the quoted closing price on Nasdaq and is classified within Level 1. The Glucotrack Series A preferred stock, which is not traded and had not been issued to the Company as of September 30, 2026, is measured on an as-converted basis using the quoted price of Glucotrack common stock and is classified within Level 2.
Assets and liabilities measured at fair value on a recurring basis were as follows:
The following table presents the changes in the Level 3 derivative liability:
Other than the reclassification of $39,331 of the derivative liability to additional paid-in capital upon the conversion of $425,000 of principal of the senior secured convertible note in September 2026 (see Note 8), there were no issuances, settlements or transfers into or out of Level 3 during the three and nine months ended September 30, 2026. There were no transfers between Level 1 and Level 2 during the periods presented.
The significant unobservable inputs used in the Monte Carlo simulation of the derivative liability as of September 30, 2026 were a share price of $5.00 on a post-split basis, annualized volatility of 165.7%, a risk-free rate of 4.54%, a remaining term of 48 trading days, a probability of default over the remaining term of 1.67%, a credit spread of 4.46% and an average realized discount from volume-weighted average price of 5.3%, simulated over 50,000 paths. Holding all other inputs constant, a 10% increase in the share price would increase the derivative liability by approximately $9,000 and a 10% decrease would reduce it by approximately $9,000; a 10 percentage-point increase in assumed volatility would increase it by approximately $1,000. The NILA Tokens are measured using quoted prices for identical assets on exchanges that are not active, adjusted for the limited number of trading venues and daily trading volume relative to the size of the Company’s position. A 10% change in the NILA price would change the carrying amount of the NILA Tokens, total digital assets and total assets by $4,968,372, or 3.2% of total assets, with a corresponding change in net income (loss). The derivative liability as of September 30, 2026 was measured on the remaining principal of $10,475,000 after the conversions described in Note 8.
Other exchange wallet balances of $6,723 at December 31, 2025 were reported within NILA tokens in Level 2 of the fair value hierarchy in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and are presented separately within Level 1 above to conform to the current-period presentation. The change is a change in disaggregation and not a transfer between levels of the fair value hierarchy, and had no effect on total digital assets, total assets, shareholders’ equity or net loss for any period presented.
The carrying amounts of cash and cash equivalents, restricted cash, other current assets, accounts payable and accrued expenses and advances payable approximate fair value because of the short-term nature of these instruments. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Convertible Instruments | Convertible Instruments
The Company evaluates the terms of its convertible instruments to determine whether any embedded features require bifurcation and separate accounting as derivatives under ASC 815. The embedded conversion feature of the Company’s senior secured convertible note was determined to require bifurcation and is carried at fair value, with changes in fair value recognized in the condensed consolidated statements of operations. The resulting discount, together with original issue discounts and issuance costs, is accreted to interest expense over the term of the instrument using the effective interest method. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Discontinued Operations | Discontinued Operations
A component of the Company that has been disposed of is reported as a discontinued operation when the disposal represents a strategic shift that has, or will have, a major effect on the Company’s operations and financial results, in accordance with ASC 205-20. The results of discontinued operations, including any gain or loss on disposal, are presented separately from continuing operations for all periods presented, and the assets and liabilities of the discontinued operation are presented separately on the condensed consolidated balance sheet for each comparative period. General corporate overhead is not allocated to discontinued operations. Interest on debt that is an obligation of the disposed component is included in discontinued operations. Gains and losses on the deconsolidation of a subsidiary are measured in accordance with ASC 810-10-40 as the fair value of consideration received less the carrying amount of the former subsidiary’s net assets (liabilities). See Note 3. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue Recognition | Revenue Recognition
The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, when control of promised goods or services transfers to a customer, in an amount that reflects the consideration to which the Company expects to be entitled. Revenue from software development and deployment services is recognized when the developed software is delivered to and accepted by the customer, which is when the Company’s performance obligation is satisfied. Invoices under the Company’s agreements are generally payable within 90 days; the Company does not adjust the consideration for a significant financing component when the period between transfer and payment is one year or less. Contract liabilities represent amounts invoiced or due before the related performance obligations are satisfied. Cost of revenue consists of the salaries of personnel and the development costs directly attributable to delivering software development and deployment services, and is expensed as incurred.
Digital Asset Yield Income. Digital asset yield income consists of bitcoin received under the Company’s digital asset yield arrangement. It is outside the scope of ASC 606 and is recognized when the bitcoin are received, measured at fair value. Beginning with the three months ended September 30, 2026, the Company presents digital asset yield income within revenue because generating yield on its bitcoin holdings is one of its principal ongoing activities. Digital asset yield income of $282,732 for the three months ended June 30, 2026, previously presented within other income (expense), is presented within revenue for the nine months ended September 30, 2026. The reclassification had no effect on net income (loss), shareholders’ equity or cash flows. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounts Receivable | Accounts Receivable
Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company measures expected credit losses on accounts receivable under ASC 326, Financial Instruments — Credit Losses, considering the customer’s credit quality, the aging of balances, current conditions and reasonable and supportable forecasts. No allowance for credit losses was recorded as of September 30, 2026. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investment in Equity Securities | Investment in Equity Securities
Equity securities with readily determinable fair values over which the Company does not have significant influence are measured at fair value in accordance with ASC 321, with changes in fair value recognized in the condensed consolidated statements of operations. The Company’s investment in Glucotrack is accounted for under this policy. See Note 5. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Concentrations of Credit Risk | Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, restricted cash and digital assets. The Company maintains cash balances at financial institutions in the United States, Singapore and the United Arab Emirates, which at times may exceed federally insured limits. As of September 30, 2026, digital assets of $142,423,473 represented 93% of the Company’s total assets, and a single asset class, Bitcoin, represented 65% of digital assets, with the NILA token representing a further 35%. Two customers accounted for all of the Company’s revenue for the three and nine months ended September 30, 2026 and all of its accounts receivable, other than accounts receivable — related party, as of September 30, 2026. Digital assets are held in custodial and exchange wallets and are subject to the credit and operational risk of those custodians and exchanges. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Segment Information | Segment Information
Following the disposal of Lokahi, the Company operates in one reportable segment, the Digital Asset segment, which comprises the digital-asset holding and trading operations and blockchain technology activities conducted through MindWave and its subsidiaries. The BioBusiness segment, which comprised the clinical-stage pharmaceutical operations conducted through Lokahi, is presented as a discontinued operation for all periods presented (see Note 3) and is excluded from the segment information below. Corporate consists of holding-company activities, including the Company’s convertible note, derivative liability, restricted cash and investment in Glucotrack. The Company’s chief operating decision makers, its , assess performance and allocate resources based on segment operating expenses and segment net loss. The Digital Asset segment commenced with the acquisition of MindWave on December 1, 2025; accordingly, no Digital Asset segment information is presented for the three and nine months ended September 30, 2025. Management has determined that the Co-Chief Executive Officers together constitute the chief operating decision maker, following the appointment of a Co-Chief Executive Officer effective May 4, 2026; they assess performance jointly, reviewing the same package of segment information, and no resource-allocation decision is made by either officer alone. The significant segment expense categories regularly provided to the chief operating decision maker is general and administrative expense, which is presented separately in the tables below. All other amounts presented for each segment — digital asset gains and losses, digital asset yield income, foreign currency gains and losses, the change in fair value of the derivative liability, the change in fair value of the investment in Glucotrack, interest income and interest expense — constitute other segment items for purposes of ASC 280-10-50-26A and are individually presented rather than aggregated. The Company does not allocate corporate overhead to the Digital Asset segment.
Three months ended September 30, 2026:
Nine months ended September 30, 2026:
Total assets by segment were as follows:
Assets of the BioBusiness as of December 31, 2025 are presented as assets of discontinued operations.
For the three and nine months ended September 30, 2025, the Company’s continuing operations consisted of corporate activities only; all operating expenses of those periods related to the BioBusiness and are presented in discontinued operations. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash, Cash Equivalents and Restricted Cash | Cash, Cash Equivalents and Restricted Cash
The Company considers all highly liquid instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Restricted cash of $8,000,000 as of September 30, 2026 (December 31, 2025 — $8,000,000) comprises $8,000,000 held in a deposit account control arrangement for the benefit of the holder of the Company’s senior secured convertible note, pending release upon conversion of the Series A Convertible Preferred Stock in accordance with the terms of the note agreement. That amount is not available for general corporate purposes. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Leases | Leases
The Company determines whether an arrangement is or contains a lease at inception. Operating leases with terms in excess of twelve months are recognized on the condensed consolidated balance sheet as a right-of-use asset and a corresponding lease liability, measured at the present value of the remaining lease payments using the Company’s incremental borrowing rate, because the rate implicit in the lease is not readily determinable. Lease cost is recognized on a straight-line basis over the lease term. See Note 13. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property and Equipment, net | Property and Equipment, net
Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three years for computer equipment and five years for furniture and fixtures. Effective February 28, 2026, the Company increased its capitalization threshold from $1,000 to $5,000; the change did not have a material effect on the condensed consolidated financial statements.
Property and equipment as of December 31, 2025 related to Lokahi and is presented within noncurrent assets of discontinued operations. Depreciation of $9,091 for the six months ended June 30, 2026 and $1,721 for the nine months ended September 30, 2025, together with amortization of the operating lease right-of-use asset of $31,233 for the six months ended June 30, 2026, is included in discontinued operations (see Note 3). |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Related Parties | Related Parties
The Company follows ASC 850, Related Party Disclosures, under which a party is considered related if it directly or indirectly controls, is controlled by, or is under common control with the Company, or if it has the ability to exercise significant influence over the Company in making financial or operating decisions. See Note 11. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| General and Administrative | General and Administrative
General and administrative expenses consist principally of salaries, benefits and share-based compensation for administrative personnel, professional and consulting fees, insurance, investor relations and other public-company costs, transaction and advisory fees, and facility costs. Advertising costs are expensed as incurred and were not material in any period presented. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Research and Development | Research and Development
Research and development costs are expensed as incurred and consist principally of salaries, benefits and share-based compensation for research personnel, contract research organization fees, clinical trial costs, non-clinical study costs, manufacturing of clinical supply, and professional consulting fees. Payments made in advance of the receipt of the related goods or services are capitalized as prepaid development costs and expensed as the goods are received or the services are performed. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-Based Compensation | Stock-Based Compensation
The Company measures share-based awards granted to employees, directors and non-employees at the grant-date fair value and recognizes the resulting expense on a straight-line basis over the requisite service period. The fair value of stock options is estimated using the Black-Scholes option-pricing model. Forfeitures are recognized as they occur. See Note 10. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Taxes | Income Taxes
The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities, measured using enacted tax rates expected to apply in the periods in which those temporary differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized. See Note 12. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net Income (Loss) per Share | Net Income (Loss) per Share
Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period, including shares committed for issuance for no further consideration. Diluted net income (loss) per share is computed by dividing net income (loss), adjusted for the effect of dilutive convertible instruments, by the weighted-average number of common shares and dilutive potential common shares outstanding, using income (loss) from continuing operations as the control number.
For the three months ended September 30, 2026, the Company reported income from continuing operations, and diluted net income per share includes the shares issuable upon conversion of the senior secured convertible note under the if-converted method: 2,723,518 weighted-average shares, computed at the conversion price of $3.992 per share in effect at September 30, 2026 (80% of the lowest daily volume-weighted average price for the five trading days ended September 30, 2026) for the period the principal was outstanding, with interest expense of $1,094,953 added back to, and the $340,411 gain from the change in fair value of the derivative liability removed from, income from continuing operations.
For the nine months ended September 30, 2026 the Company reported a loss from continuing operations, and for the 2025 periods the effect of potentially dilutive securities was anti-dilutive; accordingly, diluted net income (loss) per share equals basic net income (loss) per share for those periods.
All share and per-share amounts have been retroactively adjusted for the 1-for-10 reverse stock split effected July 24, 2026.
The following potentially dilutive securities were excluded from the computation of diluted net income (loss) per share for all periods presented:
The Series A Convertible Preferred Stock is excluded because its conversion is subject to NYSE American approval of the Company’s listing application and had not occurred as of September 30, 2026. Stock options and warrants are excluded because their exercise prices exceeded the average market price of the Company’s common stock. For the nine months ended September 30, 2026 and the 2025 periods, shares issuable upon conversion of the senior secured convertible note were also excluded because their effect would have been anti-dilutive. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Emerging Growth Company | Emerging Growth Company
The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and has elected to use the extended transition period afforded by Section 107(b) of the JOBS Act for complying with new or revised accounting standards. As a result, the Company’s financial statements may not be comparable to those of companies that comply with public-company effective dates. The Company is also a “smaller reporting company” as defined in Rule 12b-2 under the Exchange Act. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements
In December 2023, the FASB issued ASU 2023-08, Accounting for and Disclosure of Crypto Assets, which the Company has adopted and applied to its digital-asset holdings. In November 2023, the FASB issued ASU 2023-07, Segment Reporting — Improvements to Reportable Segment Disclosures, which the Company has adopted. In December 2023, the FASB issued ASU 2023-09, Income Taxes — Improvements to Income Tax Disclosures, effective for annual periods beginning after December 15, 2024, and in November 2024 the FASB issued ASU 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures, effective for annual periods beginning after December 15, 2026. The Company is evaluating the effect of ASU 2024-03 on its disclosures. Management does not believe that any other recently issued but not yet effective accounting pronouncements would have a material effect on the condensed consolidated financial statements.
In November 2024, the FASB issued ASU 2024-04, Debt — Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments, effective for annual periods beginning after December 15, 2025 and interim periods within those annual periods. The Company adopted ASU 2024-04 on January 1, 2026. The conversions of the senior secured convertible note during the three months ended September 30, 2026 were made under the original conversion terms and were not induced conversions; adoption had no effect.
In July 2025, the FASB issued ASU 2025-05, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides a practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of current accounts receivable and current contract assets arising from transactions under ASC 606. The ASU is effective for annual periods beginning after December 15, 2025 and interim periods within those annual periods. The Company has not elected the practical expedient.
In September 2025, the FASB issued ASU 2025-06, Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which removes the project-stage model and requires capitalization to begin when management has authorized and committed to funding the software project and it is probable that the project will be completed and the software used to perform its intended function. The ASU is effective for annual periods beginning after December 15, 2027 and interim periods within those annual periods, with early adoption permitted. The Company is evaluating the effect of the ASU on the accounting for its platform development costs. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||